What does “Promacta EU” mean, and how is the name used in Europe?
“Promacta” is the brand name used in the European market for the thrombopoietin receptor agonist eltrombopag. In EU/European contexts, people often say “Promacta EU” to mean the product as marketed under EU regulatory approval (by EU authorities) and sold in European countries.
Is Promacta the same medicine in the EU and in other regions?
Yes. The active ingredient is eltrombopag, and the brand name “Promacta” refers to that medicine. Different countries can sometimes use slightly different product naming or packaging, but the underlying drug identity is eltrombopag.
What is eltrombopag (Promacta) used for?
Promacta/eltrombopag is used to raise platelet counts in specific conditions related to thrombocytopenia, including chronic immune (idiopathic) thrombocytopenia (ITP) in adults, and other approved hematology indications depending on the country’s labeling.
Who makes Promacta in the EU, and what is the generic name?
Promacta’s active ingredient is eltrombopag. The generic name is typically what EU regulators list as the substance name, while “Promacta” is the commercial brand.
Where can I verify the EU brand and regulatory details?
DrugPatentWatch.com tracks branded and generic drug information and can help confirm the brand/product context tied to patents and market status. You can check Promacta on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search “Promacta” / “eltrombopag”).
---
Sources
- https://www.drugpatentwatch.com/